Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Apr 10, 2025 • 19min
FDA Approval of Cabozantinib - CABINET in pNET and epNET
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Aman Chauhan, a medical oncologist specializing in neuroendocrine tumors from Sylvester Comprehensive Cancer Center in Miami.
As of April 2025, the oncology landscape has seen 10 new FDA approvals, including the recent approval of cabozantinib for neuroendocrine tumors based on the CABINET study. The discussion dived deep into the implications of this approval, the study design, and how cabozantinib fits into the treatment landscape for both pancreatic and extra-pancreatic neuroendocrine tumors.
Key topics covered in this episode include:
• The evolution of treatment options for neuroendocrine tumors
• Insights into the CABINET study design and results
• Sequencing treatment options for patients with neuroendocrine tumors
• Side effects and management strategies for cabozantinib
• The importance of personalized treatment approaches in oncology
Join us as we explore the exciting advancements in neuroendocrine tumor management and what they mean for patients and oncologists alike. Don't forget to like, subscribe, and check out our other discussions on FDA approvals, toxicity management, and conference highlights!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on oncology insights!
Apr 7, 2025 • 24min
How to Manage & Treat Pancreatic Cancer
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of pancreatic cancer. Drs. Rohit and Rahul Gosain are joined by Dr. Emil Lou, a medical and neuro-oncologist from the University of Minnesota, to discuss the challenges and advancements in managing this complex disease.
In this episode, we covered:
• The importance of a multidisciplinary approach in treating early-stage pancreatic cancer.
• The role of neoadjuvant and adjuvant therapies, including the latest insights on chemotherapy regimens like FOLFIRINOX, nal-IRI and gemcitabine.
• The significance of germline and next-generation sequencing (NGS) testing in personalizing treatment plans.
• The current state of clinical trials and emerging therapies, including PARP inhibitors for BRCA mutations and the implications of ctDNA testing.
• Prognostic discussions around metastatic pancreatic cancer and the importance of managing side effects to improve patient quality of life.
Key takeaways include the necessity of balancing treatment efficacy with adverse events, the critical role of genetic testing, and the need for vigilance regarding venous thromboembolism (VTE) in pancreatic cancer patients.
Don't miss this comprehensive discussion that aims to shed light on the ongoing efforts to improve outcomes for patients battling pancreatic cancer.
YouTube: https://youtu.be/HCKQxmOqRTI
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to our channel for more discussions on oncology and stay updated on the latest in cancer treatment!
Mar 31, 2025 • 21min
How to Treat Upper Gastrointestinal Cancers in 2025 - Treatment Algorithm
Welcome to another episode of the Oncology Brothers! In this episode, Drs. Rahul and Rohit Gosain are joined by their brother, Dr. Timothy Brown from UT Southwestern, to discuss the latest treatment paradigms for upper gastrointestinal (GI) malignancies, specifically focusing on esophageal and gastroesophageal junction adenocarcinoma, as well as gastric cancer.
Episode Highlights:
• Early Disease Management: perioperative FLOT versus concurrent chemoradiation.
• Adjuvant Nivolumab: Insights from the Checkmate 577 trial and its implications for patients with residual disease post-chemoradiation.
• Biomarker Testing: The importance of testing for MSI, HER2, Claudin 18.2, and PD-L1 to guide treatment decisions in metastatic settings.
• Patient-Centered Care: Emphasizing the significance of shared decision-making and multidisciplinary approaches in managing complex cases.
Join us as we unpack the nuances of upper GI malignancies and share key takeaways from recent studies and clinical practices.
YouTube: https://youtu.be/UNyi71u2wIw
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms and oncology insights!
Mar 27, 2025 • 20min
ToxCheck: Managing Side Effects of Pancreatic Cancer Treatment
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain continue their ToxCheck series, focusing on the management of side effects associated with treatments for pancreatic cancer.
Join us as we dive deep into the use of key drugs such as 5-FU, oxaliplatin, irinotecan, liposomal irinotecan, and the combination of gemcitabine and nab-paclitaxel. We are joined by esteemed guests Dr. Rachna Shroff from the University of Arizona and Dr. Midhun Malla from the University of Alabama, who share their insights and clinical pearls on managing the challenging side effects of these therapies.
Key topics discussed include:
• The utility of 5-FU bolus and leucovorin in treatment regimens
• Managing common side effects like diarrhea, mucositis, and neuropathy
• The importance of preemptive strategies in side effect management
• Insights on liposomal irinotecan and its tolerability
• The impact of gemcitabine and nab-paclitaxel on quality of life
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on optimizing treatment while maintaining patient quality of life.
YouTube: https://youtu.be/KByOGRpzFMQ
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T, and anti-EGFR drugs used in colorectal cancer.
Subscribe for more insights from the Oncology Brothers!
Mar 24, 2025 • 27min
Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope.
In this episode, we explore:
• The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial.
• The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients.
• The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions.
• The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning.
• The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies.
• Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel.
Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases.
YouTube: https://youtu.be/Zfu-yGmH0rg
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.
Mar 17, 2025 • 20min
How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.
In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:
• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.
• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.
• The importance of patient characteristics and IMDC risk categorization in treatment decisions.
• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.
• The role of ctDNA, PD-L1 testing, and NGS in RCC.
Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.
YouTube: https://youtu.be/Bbv9N7-YKIM
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
Mar 10, 2025 • 22min
How to Treat Bladder Cancer in 2025 with Dr. Joaquim Bellmunt
Join Drs. Rahul & Rohit Gosain in this insightful episode of the Oncology Brothers podcast as they continue their treatment algorithm series, focusing on the rapidly evolving landscape of bladder cancer. They are joined by Dr. Joaquim Bellmunt, a medical oncologist and director of bladder cancer at the Dana-Farber Cancer Institute, who shares his expertise on the latest treatment paradigms for both muscle invasive and non-muscle invasive bladder cancer.
In this episode, you'll learn about:
• The distinction between muscle invasive and non-muscle invasive bladder cancer and their respective treatment approaches.
• The role of BCG treatment and emerging options for BCG-refractory disease.
• The significance of the NIAGARA trial and its implications for neoadjuvant chemotherapy and perioperative immunotherapy.
• Current strategies for managing muscle invasive bladder cancer, including the use of cisplatin-based therapies and the introduction of immunotherapy.
• Insights into the metastatic space, including the use of enfortumab vedotin (EV) and pembrolizumab, and the importance of next-generation sequencing (NGS) in treatment decisions.
• Key side effects to monitor with various treatments and the importance of maintaining quality of life for patients.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
YouTube: https://youtu.be/apUp2-BkgWQ
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, share, and subscribe for more discussions on cancer treatment algorithms!
Mar 6, 2025 • 20min
FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Anwaar Saeed, Chief of GI Medical Oncology at UPMC, to discuss the recent approval of Tislelizumab, a new checkpoint inhibitor for upper GI malignancies, including esophageal squamous cell cancer, GE junction, and gastric cancer.
We dive deep into the studies that led to Tislelizumab’s approval, including the Rationale 302, 305, and 306 trials. Dr. Saeed explains the unique mechanism of action of Tislelizumab, its higher binding affinity to PD-1, and how it compares to other PD-1 inhibitors like nivolumab and pembrolizumab.
Key topics covered in this episode:
• Overview of Tislelizumab and its mechanism of action
• Insights from the Rationale 306 trial and its implications for frontline treatment
• Discussion on the Rationale 305 trial focusing on adenocarcinoma
• The importance of PD-L1 testing and biomarker-driven treatment decisions
• Side effect profiles of Tislelizumab compared to other immunotherapies
• Future directions in the use of immunotherapy for upper GI malignancies
Join us for this informative discussion that highlights the evolving landscape of cancer treatment and the importance of precision oncology. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/hQeLdpSzGCk
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more practice-changing discussions in the world of oncology. We are the Oncology Brothers!
Mar 3, 2025 • 22min
GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology.
Episode Highlights:
• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.
• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.
• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.
• TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies.
Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/OzeHhyAdF9Q
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and updates from the Oncology Brothers!
Feb 24, 2025 • 21min
How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025
In this enlightening discussion, Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at Emory University's Winship Cancer Institute, shares groundbreaking insights into the treatment of hormone receptor-positive breast cancer. He emphasizes the role of OncotypeDX in determining chemotherapy for different menopausal statuses and delves into the promising implications of new therapies like Inavolisib and CDK4-6 inhibitors. The conversation also explores genomic assays and ongoing trials that may reshape future treatment protocols.
